Agewell Brief

Agewell Brief · Research Radar · Sample issue

A real issue, computed live — not a mockup

This page renders straight from the same archive and scripts as every subscriber issue. Nothing here is written to look impressive; it's whatever the archive actually produced this month.

The Agewell Brief Editorial Desk · Published monthly

Archive: 2024-01-01 to 2026-08-10 114 briefs
Every finding below traces to a dated brief — or a ClinicalTrials.gov trial ID — you can click through and check. Full methodology: agewellbrief.com/research-radar-methodology.

Confidence Shifts Within a Topic

Pairs of briefs tagged with the same topic where the later brief sits higher on the evidence ladder than the earlier one, at least 7 days apart.

This tracks a topic tag, not a single mechanism — the two briefs below are often different findings that happen to share a topic, not the same claim re-confirmed.

Mobility

366 days

1 pair(s) found across 64 briefs tagged with this topic.

Brain Health

367 days

1 pair(s) found across 65 briefs tagged with this topic.

Detoxification

335 days

1 pair(s) found across 26 briefs tagged with this topic.

Cross-Framework Convergence

Historical antecedents independently cited by briefs in unrelated categories — a signal that disparate current research is converging on the same underlying mechanism.

Tomas Lindahl

3 briefs

Cited independently across 3 categories: brain health, longevity, metabolic health.

Christian de Duve

3 briefs

Cited independently across 3 categories: cellular senescence, longevity, metabolic health.

Leonard Hayflick

7 briefs

Cited independently across 3 categories: cellular senescence, longevity, metabolic health.

Judith Campisi

4 briefs

Cited independently across 3 categories: cellular senescence, longevity, metabolic health.

All 4 of these briefs also cite Leonard Hayflick — read alongside that entry, not as an independent signal.

Peter Mitchell

5 briefs

Cited independently across 3 categories: brain health, cellular senescence, metabolic health.

Institutional Signal: Trial Registry Activity Prototype

For each brief, the single most specific named compound or intervention (if any) is checked against ClinicalTrials.gov.

20 of 114 briefs named something specific enough to check. Terms matching 150+ unrelated trials are excluded as noise, not signal.

Litevax Adjuvant

1 active

3 trial(s) on ClinicalTrials.gov. Named in: An experimental flu adjuvant sped early antibody quality in over-60s.

  • NCT05581407 — COMPLETED, phase PHASE1, LiteVax BV
  • NCT06294262 — UNKNOWN, phase PHASE1/PHASE2, LiteVax BV
  • NCT06986239 — NOT_YET_RECRUITING, phase PHASE1, LiteVax BV

Dihydromyricetin

1 active

4 trial(s) on ClinicalTrials.gov. Named in: Flavonoid from vine tea selectively clears senescent microglia, repairs DNA in aging cells.

  • NCT06575972 — COMPLETED, phase NA, Joyrise
  • NCT05623501 — NOT_YET_RECRUITING, phase PHASE1, University of Southern California
  • NCT03606694 — UNKNOWN, phase PHASE2, University of Guadalajara
  • NCT05757089 — UNKNOWN, phase NA, AVVA Pharmaceuticals Ltd.

Rankl Inhibitor

3 active

11 trial(s) on ClinicalTrials.gov. Named in: RANKL blockade: one molecule, three wins—bone, muscle, lifespan.

  • NCT03520231 — COMPLETED, phase PHASE2, University Health Network, Toronto
  • NCT03259152 — UNKNOWN, phase PHASE3, Hebei Medical University Third Hospital
  • NCT06302465 — RECRUITING, phase NA, Peking University People's Hospital
  • NCT01624766 — COMPLETED, phase PHASE1, M.D. Anderson Cancer Center

Senolytic

6 active

23 trial(s) on ClinicalTrials.gov. Named in: What the cell-shedding framework gets right about senescence research, Targeting senescence: the new precision arsenal against aging.

  • NCT05482672 — WITHDRAWN, phase PHASE2/PHASE3, Cale Andrew Jacobs, PhD
  • NCT05653258 — RECRUITING, phase PHASE2/PHASE3, Cedars-Sinai Medical Center
  • NCT06018467 — ACTIVE_NOT_RECRUITING, phase PHASE2, Odense University Hospital
  • NCT07637487 — RECRUITING, phase NA, National University of Malaysia

Urolithin A

3 active

32 trial(s) on ClinicalTrials.gov. Named in: Urolithin A restores calcium-driven organelle crosstalk to trigger mitophagy and slow ageing.

  • NCT07060898 — ACTIVE_NOT_RECRUITING, phase NA, Amazentis SA
  • NCT04075032 — COMPLETED, phase NA, National Research Council, Spain
  • NCT06140602 — UNKNOWN, phase NA, University of Georgia
  • NCT06619457 — COMPLETED, phase NA, Amazentis SA

Hypoglossal Nerve Stimulation

6 active

62 trial(s) on ClinicalTrials.gov. Named in: Nerve stimulation for sleep apnea showed wider health gains.

  • NCT07577661 — NOT_YET_RECRUITING, phase PHASE1/PHASE2, Brigham and Women's Hospital
  • NCT07303452 — RECRUITING, phase NA, Restera, Inc.
  • NCT06851338 — RECRUITING, phase NA, Inspire Medical Systems, Inc.
  • NCT04768543 — COMPLETED, phase N/A, University of Pittsburgh

Nicotinamide Riboside

5 active

121 trial(s) on ClinicalTrials.gov. Named in: Nicotinamide riboside and hard training remodelled muscle epigenetics differently.

  • NCT03642990 — TERMINATED, phase PHASE2, Donna Hammond, PhD
  • NCT07344636 — RECRUITING, phase NA, ZHANG Jiaqi
  • NCT06005350 — UNKNOWN, phase NA, Charite University, Berlin, Germany
  • NCT03727646 — COMPLETED, phase EARLY_PHASE1, University of Washington

11 more term(s) matched but were too broad to be meaningful signal: intermittent fasting, time-restricted eating, interval walking, melatonin, protein restriction, semaglutide, mediterranean diet, statin, omega-3 fatty acids, lifestyle intervention, exercise.

Research Radar publishes monthly, $399/mo or $3,990/yr.

See pricing & start a conversation →